Global Downstream Market Size Likely to Surpass at a CAGR of 14.2% By 2033

As per the current market research conducted by CMI Team, the global Downstream Market size is expected to record a CAGR of 14.2% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 28.5 billion. By 2032, the valuation is anticipated to reach USD 76.8 billion.

Downstream Market: Growth Factors and Dynamics

• Increasing Biopharmaceutical Production: The exponential growth in demand for biopharmaceutical products, such as vaccines, monoclonal antibodies, and therapeutic proteins, is propelling the need for efficient downstream processing techniques. The ability to purify and isolate these complex molecules with precision and high yields is crucial to meet the surging global healthcare requirements and combat various diseases effectively.

• Advancements in Technology: Rapid technological innovations are revolutionizing downstream processing, introducing cutting-edge solutions like high-throughput chromatography, continuous processing, and single-use technologies. These advancements have streamlined production processes, reduced operational costs, and accelerated product development timelines, contributing to enhanced efficiency and scalability in the biopharmaceutical industry.

• Rising Biotechnology Investments: Substantial investments in biotechnology and biopharmaceutical research and development are driving the expansion of downstream processing capabilities. Pharmaceutical companies and biotechnology firms are dedicating significant resources to optimize downstream processing workflows, ensuring seamless integration with upstream processes and facilitating the commercial production of biologics.

• Stringent Quality Regulations: Stringent quality and safety regulations imposed by global regulatory authorities have placed a greater emphasis on the reliability and efficacy of biopharmaceutical products. As a result, manufacturers are increasingly adopting advanced downstream processing techniques to ensure stringent adherence to quality standards, consistent product purity, and minimized risk of contamination.

• Shift towards Personalized Medicine: The paradigm shift towards personalized medicine and gene therapies is reshaping the downstream processing landscape. Manufacturers are confronted with the challenge of handling smaller batch sizes, diverse product profiles, and intricate manufacturing processes. In response, downstream processing solutions are becoming more adaptable and flexible, allowing biomanufacturers to meet the unique needs of individual patients.

• Adoption of Continuous Bioprocessing: The downstream processing market is witnessing an increasing adoption of continuous bioprocessing, a paradigm shift from traditional batch processing. Continuous bioprocessing offers numerous advantages, including reduced production time, increased productivity, minimized operator interventions, and enhanced product consistency.

Downstream Market: Partnership and Acquisitions

• Thermo Fisher Scientific Inc. and CSL Limited: In 2020 Thermo Fisher Scientific, a prominent biotechnology company, partnered with CSL Limited, a leading global biotech company. The collaboration aimed to advance downstream processing technologies for plasma-derived therapies. Thermo Fisher provided expertise in purification systems, while CSL contributed its knowledge in plasma fractionation.

• Siemens technology group and Sartorius Stedim Biotech: In 2018, The Siemens technology group and Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, have agreed on long-term cooperation in the area of automation. This agreement provides that Sartorius Stedim Biotech will preferably use Siemens automation technologies, which will include industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC, among others.

Report Scope

Downstream Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Downstream Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Supply Chain Disruptions: The pandemic caused disruptions in global supply chains, affecting the availability of raw materials and critical components required for downstream processing. Delays in shipments and logistics challenges impacted production timelines and led to uncertainties in the market.

• Shift in Priorities: During the pandemic, the biopharmaceutical industry redirected its focus towards the development and production of COVID-19 vaccines and therapeutics. Non-COVID related biopharmaceutical projects experienced delays or reduced investments, affecting downstream processing activities.

• Resilience through Digitization: Companies are adopting digital solutions to improve process efficiency, data management, and remote monitoring, ensuring better resilience against future disruptions and enabling seamless operations.

• Diversification of Supply Chains: Biopharmaceutical manufacturers are diversifying their supply chains and establishing alternate sourcing options for critical raw materials, reducing dependence on specific regions and enhancing supply chain stability.

• Rapid Technological Advancements: The pandemic accelerated technological innovations in downstream processing, such as continuous bioprocessing and automation, enabling faster production and improved efficiency in response to changing market demands.

• Recovery of Non-COVID Projects: With the easing of pandemic-related restrictions and healthcare systems stabilizing, focus on non-COVID biopharmaceutical projects is gradually resuming, contributing to increased downstream processing activities and overall market recovery.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Downstream Market, with some challenges and opportunities arising from the pandemic. Manufacturers and retailers need to remain agile and adapt to the changing market conditions to overcome these challenges and capitalize on new growth opportunities.

List of the prominent players in the Downstream Market:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• General Electric Company (GE Healthcare)
• Sartorius AG
• Danaher Corporation (Pall Corporation)
• 3M Company (3M Purification Inc.)
• Repligen Corporation
• Agilent Technologies Inc.
• Eppendorf AG
• MilliporeSigma (Sigma-Aldrich Corporation)
• Others

The Downstream Market is segmented as follows:

By Product  

• Centrifuges
• Dryers
• Chromatography Systems
• Filters
• Evaporators
• Others

By Application

• Antibodies Production
• Antibiotic Production
• Hormone Production
• Enzyme Production
• Vaccine Production

By Technique

• Purification by Chromatography
• Solid-liquid Separation
• Cell Disruption
• Concentration
• Formulation

By Region

North America

• The U.S.
• Canada
• Mexico

Europe

• France
• The UK
• Spain
• Germany
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America